Predictors of thrombosis in children receiving therapy for acute lymphoblastic leukemia: Results from Dana-Farber Cancer Institute ALL Consortium trial 05-001.
Uma H AthaleYael FlamandTraci BlonquistKristen E StevensonMenachem SpiraBarbara L AsselinLuis A ClavellPeter D ColeKara M KellyCaroline LaverdiereJean-Marie LeclercBruno MichonMarshall A SchorinJennifer J G WelchMarian H HarrisDonna S NeubergStephen E SallanLewis B SilvermanPublished in: Pediatric blood & cancer (2022)
We recommend further evaluation of these risk factors and consideration of thromboprophylaxis for patients ≥10 years (especially those ≥15 years) when receiving asparaginase.
Keyphrases
- acute lymphoblastic leukemia
- risk factors
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- clinical trial
- young adults
- pulmonary embolism
- venous thromboembolism
- papillary thyroid
- prognostic factors
- study protocol
- peritoneal dialysis
- patient reported outcomes
- phase ii
- allogeneic hematopoietic stem cell transplantation
- direct oral anticoagulants